# US 2006/0052591 A1 · Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052591 A1
- Document ID: US20060052591A1
- Status: Published application
- Kind: A1
- Application number: 10/311,822
- Filed: 2001-01-25
- Published: 2006-03-09
- Earliest claimed: 2000-01-25
- Inventors: Bryan Boyle; Chiaoyun Kuo; Matthew Arterburn; Y Tang; Chenghua Liu; Radoje Drmanac
- Web page: https://patentgrep.com/patent/US20060052591A1

## CPC

- C12N 9/6432: {Coagulation factor Xa (3.4.21.6)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/70503: {Immunoglobulin superfamily}
- C12Y 304/21006: Coagulation factor Xa (3.4.21.6)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleoddes and mutants or variants thereof that correspond to a novel human secreted CEA-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from rectum (Hyseq clone identification numbers 15456780 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CEA-like polypeptides, and antibodies specific for such polypeptides.

## Claims

### Claim 1

An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 2-3 and 5, the translated protein coding portion thereof, the mature protein coding portion thereof, the extracellular portion thereof, or the active domain thereof.

### Claim 2 (depends on 1)

An isolated polynucleotide encoding a polypeptide with biological activity, which polynucleotide hybridizes to the complement of a polynucleotide of claim 1 under stringent hybridization conditions.

### Claim 3 (depends on 1)

An isolated polynucleotide encoding a polypeptide with biological activity, said polynucleotide having greater than about 90% sequence identity with the polynucleotide of claim 1.

### Claim 4 (depends on 1)

The polynucleotide of claim 1 which is a DNA sequence.

### Claim 5 (depends on 1)

An isolated polynucleotide which comprises the complement of the polynucleotide of claim 1.

### Claim 6 (depends on 1)

A vector comprising the polynucleotide of claim 1.

### Claim 7 (depends on 1)

An expression vector comprising the polynucleotide of claim 1.

### Claim 8 (depends on 1)

A host cell genetically engineered to express the polynucleotide of claim 1.

### Claim 9 (depends on 8)

The host cell of claim 8 wherein the polynucleotide is in operative association with a regulatory sequence that controls expression of the polynucleotide in the host cell.

### Claim 10

An isolated polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 4 and 6-10, the translated protein coding portion thereof, the mature protein coding portion thereof, the extracellular portion thereof, or the active domain thereof.

### Claim 11 (depends on 10)

A composition comprising the polypeptide of claim 10 and a carrier.

### Claim 12

A polypeptide, having CEA-like activity, comprising at least ten consecutive amino acids from the polypeptide sequences selected from the group consisting of SEQ ID NO: 4 and 6-10.

### Claim 13 (depends on 12)

The polypeptide of claim 12, comprising at least five consecutive amino acids from the polypeptide sequences selected from the group consisting of SEQ ID NO. 4 and 6-10.

### Claim 14 (depends on 12)

A polynucleotide encoding a polypeptide according to claim 12.

### Claim 15 (depends on 13)

A polynucleotide encoding a polypeptide according to claim 13.

### Claim 16 (depends on 10)

A polynucleotide encoding a polypeptide according to claim 10.

### Claim 17 (depends on 10)

An antibody specific for the polypeptide of claim 10.

### Claim 18 (depends on 1)

A method for detecting the polynucleotide of claim 1 in a sample, comprising:
a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and
b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

### Claim 19 (depends on 1)

A method for detecting the polynucleotide of claim 1 in a sample, comprising:
a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;
b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and
c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

### Claim 20 (depends on 19)

The method of claim 19, wherein the polynucleotide comprises an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

### Claim 21 (depends on 10)

A method for detecting the polypeptide of claim 10 in a sample, comprising:
a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and
b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.

### Claim 22 (depends on 10)

A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
a) contacting the compound with the polypeptide of claim 10 under conditions and for a time sufficient to form a polypeptide/compound complex; and
b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

### Claim 23 (depends on 10)

A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
a) contacting the compound with the polypeptide of claim 10, in a cell, for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and
b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

### Claim 24 (depends on 8)

A method of producing a CEA-like polypeptide, comprising,
a) culturing the host cell of claim 8 under conditions sufficient to express the polypeptide in said cell; and
b) isolating the polypeptide from the cell culture or cells of step (a).

### Claim 25 (depends on 10)

A kit comprising the polypeptide of claim 10.

### Claim 26 (depends on 1)

A nucleic acid array comprising the polynucleotide of claim 1 or a unique segment of the polynucleotide of claim 1 attached to a surface.

### Claim 27 (depends on 1, 26)

The array of claim 26, wherein the array detects full-matches to the polynucleotide or a unique segment of the polynucleotide of claim 1.

### Claim 28 (depends on 1, 26)

The array of claim 26, wherein the array detects mismatches to the polynucleotide or a unique segment of the polynucleotide of claim 1.

### Claim 29 (depends on 10)

A method of treatment of a subject in need of enhanced activity or expression of CEA-like polypeptide of claim 10 comprising administering to the subject a composition selected from the group consisting of:
(a) a therapeutic amount of a agonist of said polypeptide;
(b) a therapeutic amount of the polypeptide; and
(c) a therapeutic amount of a polynucleotide encoding the polypeptide in a form and under conditions such that the polypeptide is produced, and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 10)

A method of treatment of a subject having need to inhibit activity or expression of CEA-like polypeptide of claim 10 comprising administering to the subject a composition selected from the group consisting of:
(a) a therapeutic amount of an antagonist to said polypeptide;
(b) a therapeutic amount of a polynucleotide that inhibits the expression of the nucleotide sequence encoding said polypeptide; and
(c) a therapeutic amount of a polypeptide that competes with the CEA-like polypeptide for its ligand
and a pharmaceutically acceptable carrier.
